The relationship between daily calcium intake and bone mineral density in men with prostate cancer

BJU International

Volumn 99, Issue 4, 2007, Pages 812-816

  Planas, Jacques ^a   Morote, Juan ^a   Orsola, Anna ^a   Salvador, Carlos ^a   Trilla, Enrique ^a   Cecchini, Lluis ^a   Raventós, Carles X ^a   Morin, Jacques P ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Androgen deprivation therapy; Calcium intake; Osteoporosis; Prostate cancer

Indexed keywords

CALCIUM; GONADORELIN AGONIST; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE METASTASIS; CALCIUM INTAKE; CANCER PATIENT; CANCER THERAPY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; HEALTH CARE ORGANIZATION; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUESTIONNAIRE; RISK FACTOR; ADVANCED CANCER; DAIRY PRODUCT; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAT INTAKE; NOTE; OSTEOPENIA; PATIENT MONITORING; VITAMIN SUPPLEMENTATION;

EID: 33947328243     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06695.x     Document Type: Article

References (20)

1. Wasson JH, Splaine ME, Bazos D, Fisher ES. Overview: working inside, outside, and side by side to improve the quality of health care. Jt Comm J Qual Improv 1998; 24: 513-7
2. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-44
3. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83: 1561-6
4. Wei JT, Gross M, Jaffe CA et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999; 54: 607-11
5. Higano CS. Management of bone loss in men with prostate cancer. J Urol 2003; 170: S59-64
6. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-6
7. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-55
8. Morote J, Martinez E, Trilla E et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 2003; 44: 661-5
9. Morote J, Orsola A, Abascal JM et al. Bone mineral density changes in prostate cancer patients during the first two years of androgen suppression. J Urol 2006; 175: 1679-83
10. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-64
11. Oefelein MG, Resnick MI. The impact of osteoporosis in men treated for prostate cancer. Urol Clin North Am 2004; 31: 313-9
12. NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA 1994; 272: 1942-8
13. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6
14. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001; 91: 2238-45
15. Cauley JA, Fullman RL, Stone KL et al. Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 2005; 16: 1525-37
16. Agarwal MM, Khandelwal N, Mandal AK et al. Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer 2005; 103: 2042-52
17. Ebeling PR, Wark JD, Yeung S et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study. J Clin Endocrinol Metab 2001; 86: 4098-103
18. Peacock M, Liu G, Carey M et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 2000; 85: 3011-9
19. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-10
20. Hussain SA, Weston R, Stephenson RN, George E, Parr NJ. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 2003; 92: 690-4